生物活性肽对端粒长度的影响

Effect of bioactive peptides on telomere length

目的评价生物活性肽对端粒长度的影响。方法采用多中心、随机、双盲、安慰剂平行对照研究试验设计,试验受试者分为4组,每组50人。前3组分别口服生物活性肽2、4、6 g/d;对照组口服安慰剂。疗程均为9个月。应用荧光实时定量PCR法检测端粒长度,检测实验前以及试验后3个月、6个月和9个月的外周血端粒长度,评价生物活性肽对端粒长度的影响作用。结果对比服用生物活性肽前,全分析集(FAS)分析提示经过3个月,4组受试者端粒缩短率分别为1.42‰、1.42‰、1.48‰和1.48‰,差异不明显(P=0.0678);口服生物活性肽满6个月时,4组受试者端粒缩短率分别为2.55‰、2.20‰、1.66‰和2.91‰,端粒缩短程度出现了变化(P=0.0415);口服生物活性肽满9个月时,端粒缩短率分别为3.44‰、2.97‰、1.90‰和4.15‰,端粒缩短程度出现了差异(P=0.0403)。结论生物活性肽有延缓端粒缩短的作用。

Objective To evaluate the effect of bioactive peptides on telomere length. Methods A multicenter, double-blind, randomized and placebo controlled trial of bioactive peptides on telomere length was conducted. The subjects were divided into 4 groups： trial group A（n = 50）, trial group B（n = 50）, trial group C（n = 50） and placebo group（group D, n = 50）, and then treated with bioactive peptides 2, 4, 6 g/d and placebo, respectively. The treatment lasted for9 months. Real-time quantitative PCR was used to measure the telomere length, before and after treatment for 3, 6 and 9 months in the peripheral blood, to evaluate the effect of bioactive peptides on telomere length. Results FAS（full analysis set） analysis showed that reduction of telomere length rate were 1.42‰, 1.42‰, 1.48‰ and 1.48‰, respectively, after 3 months trial. And 2.55‰, 2.20‰, 1.66‰ and 2.91‰, respectively, after 6 months trial. And 3.44‰, 2.97‰, 1.90‰ and 4.15‰, respectively, after 9 months trial in group A, group B, group C, and group D. Analysis showed that the telomere length in the four groups were shortened without significant difference after 3 months（P = 0.0678）. However, the difference between the four groups is obvious after 6 months and significant after 9 months（P〈0.05）. Conclusions The long-term use of bioactive peptides may delay the reduction of telomere length.